Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option
★★★★★ 3rd-party
External rating
- Source: Third-party data provider (Groww/CRISIL)
- Original rating: 2/5, displayed as-is — TopFund does not modify third-party ratings
- Refresh frequency: Whenever TopFund re-syncs this fund's data
- Limitations: The provider's own rating methodology isn't disclosed here — see the provider's own site for their criteria
TopFund Score: 70/100 · Good
How this score is calculated
- Star rating (35%)2/5
- 3Y CAGR (30%)18.96%
- Expense ratio (20%)0.99%
- AUM (15%)₹9,166 Cr
Not investment advice — an analytical read of public fund data. Methodology →
Nippon India Mutual Fund · Equity · Sectoral
₹646.81
AUM: ₹9,166 Cr
NAV updated 13 days ago
Plan
Direct
Option
Growth
Risk
Very High
Expense Ratio
0.99%
Exit Load
Exit load of 1% if redeemed within 1 month.
Fund Manager
Sailesh Raj Bhan
Inception
Jan 2013
Benchmark
BSE Healthcare Total Return Index
Sharpe Ratio
0.49
Std Dev (1Y)
12.48%
Historical Returns (CAGR)
Annualized trailing returns computed from NAV history — past performance only, not a guarantee of future results.
1m
+3.04%
3m
+0.74%
6m
+7.9%
1y
+10.92%
3y
+18.96%
5y
+14.59%
10y
+16.08%
since inception
+17.4%
TopFund's Take on Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option
Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option holds up reasonably well within the Sectoral category, currently carrying a 2-star rating. TopFund's composite Health Score, which weighs rating, 3-year CAGR, expense ratio and fund size, puts it at 70/100.
Cost: At 0.99%, the expense ratio is roughly in line with the Sectoral category average of 1.0% — cost isn't a standout factor either way for this fund.
Risk-adjusted performance: Over the trailing 1-year period, the fund shows a modest Sharpe ratio of 0.49 — returns have only marginally compensated for the risk taken. Separately, annualised volatility of 12.48% is fairly typical for Sectoral funds.
Who should invest: This fund is best suited to investors whose goals and risk appetite align with a Equity fund. Given the Very High risk rating, this fund is not suited to short-term goals or investors who may need to exit within 2-3 years.
This is an automated, data-driven analysis based on the fund's own metrics and its category peers — not personalized investment advice. Consult a SEBI-registered advisor before investing.
Sector Allocation
Asset Allocation
Fund Snapshot
Similar Funds
SBI Arbitrage Opportunities Fund - Direct Plan - Gr
SBI Mutual Fund
Franklin India Technology Fund-Growth
Franklin Templeton Mutual Fund
SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH
SBI Mutual Fund
DSP Nifty Healthcare Index Fund - Direct- Growth
DSP Mutual Fund
Franklin India Technology Fund - Direct - Growth
Franklin Templeton Mutual Fund
BANK OF INDIA Manufacturing & Infrastructure Fund-Growth
Bank of India Mutual Fund
Tools & Guides for This Fund
Frequently Asked Questions about Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option
The current NAV (Net Asset Value) of Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option is ₹646.81. NAV is updated every business day after market close by AMFI.
1Y: 10.92% · 3Y CAGR: 18.96% · 5Y CAGR: 14.59%
The expense ratio of Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option is 0.99% per annum. This is the annual fee charged by the fund to manage your investment.
Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option is managed by Sailesh Raj Bhan at Nippon India Mutual Fund.
Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option is classified as a Very High risk fund. It is suitable for aggressive investors with a long-term horizon of 5+ years.
Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option is a Sectoral fund. SIP suitability depends on your investment goal and risk profile.
You can start a SIP in Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option with as little as ₹500 per month through most mutual fund platforms. The minimum lump sum investment is typically ₹1,000.
The Assets Under Management (AUM) of Nippon India Pharma Fund - Direct Plan Growth Plan - Bonus Option is ₹9,166 crore. AUM indicates the total market value of assets managed by the fund.
* Past performance is not indicative of future results. Mutual fund investments are subject to market risks.
Discussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.